000			03683nam a22003137a 4500
003			KOHA
005			20230417095221.0
008			230214d2022 cy ||||| m||| 00| 0 eng d
040			_aCY-NiCIU _beng _cCY-NiCIU _erda
041			_aeng
090			_aYL 2691 _bH67 2022
100	1		_aHosseini, Rouminasadat
245	1	4	_aTHE EFFECT OF COMBINATORIAL THERAPEUTICS ON BREAST CANCER CELLS USING NANOPARTICLE DRUG DELIVERY SYSTEM / _cROUMINASADAT HOSSEINI; SUPERVISOR: DR. DERAN ERDENGIZ
264			_c2022
300			_a55 sheets; _c31 cm. _eIncludes CD
336			_2rdacontent _atext _btxt
337			_2rdamedia _aunmediated _bn
338			_2rdacarrier _avolume _bnc
502			_aThesis (MSc) - Cyprus International University. Institute of Graduate Studies and Research Bioengineering Department
504			_aIncludes bibliography (sheets 47-55)
520			_aABSTRACT Breast cancer is one of the most common types of cancer with an estimated incidence rate of 2.26 million in 2020 and ranked number one as leading cause of cancer mortality in women. So far it has been treated and controlled by conventional therapies such as chemotherapy, radiation therapy and surgery. Since 2010, nanoparticle drug delivery systems have demonstrated great potential in the treatment of cancers. When compared to conventional therapeutics, the advantages of nanoparticles include lower side effects, higher biocompatibility, and greater stability, enhanced targeting, and lower toxicity. So far various types of nanoparticles, such as albumin, iron oxide, gold and silver nanoparticles have shown great potential in cancer treatment and drug delivery; furthermore, recent studies have shown that ZnO nanoparticles (NPs) have cytotoxic effect on cancer cells and can induce apoptosis by generating cellular oxidative stress. In addition, researchers are using drug-repurposing methods to further the development of cancer therapeutics. Experimental data have shown that metformin, which is originally a type-2 diabetes treatment drug, also has anticancer potentials and can reduce the proliferation of cancer cells. We hypothesized that combinatorial exposure of ZnO and metformin-encapsulated carboxymethyl chitosan (MeCMC) NPs will generate enhanced cytotoxicity and apoptosis, as well as reduced proliferation in breast cancer cells, compared to single exposure of either one over time. To answer our hypothesis, we used MDA-MB-231, triple negative breast cancer cell lines, to assess the differences between combinatorial exposure of ZnO and MeCMC NPs and their effect alone. The results obtained from the experiment did not show a significant difference in the cell viability between single and double exposure when comparing the same concentration of both CMC NP and metformin, however, it showed a significant decrease of cell viability by comparing the same dose of the drug in different concentrations of CMC NP between single and double exposure. In addition, our results indicate that even though combinatorial exposure did not show a significant change in viability, it may have a significant effect on cell proliferation. Keywords: Breast cancer, Carboxymethyl Chitosan, Combinatorial Therapeutics, Drug Delivery, Drug Repurposing, Metformin, Nanoparticle, Zinc Oxide
650		0	_aBreast _vDissertations, Academic _xCancer
650		0	_aDrug delivery systems _vDissertations, Academic
650		0	_aMetformin _vDissertations, Academic
650		0	_aNanoparticles _vDissertations, Academic
700	1		_aErdengiz, Deran _esupervisor
942			_2ddc _cTS
999			_c289731 _d289731